Controversies and consensuses on neoadjuvant therapy for lung cancer
JIN Yi-nuo
WANG Qi
Abstract：For patients with potentially resectable lung cancer,neoadjuvant therapy is crucial and plays a key role in improving the overall prognosis of those with locally advanced lung cancer.Neoadjuvant therapy for lung cancer includes neoadjuvant targeted therapy,neoadjuvant immunotherapy,and neoadjuvant chemoradiotherapy,which have demonstrated significant efficacy in shrinking tumor lesions and reducing tumor staging.This,in turn,provides more surgical options and helps reduce the risk of postoperative recurrence and distant metastasis.Multiple cohort studies have confirmed that,compared to surgery alone,neoadjuvant therapy can provide long-term therapeutic benefits.Currently,there is consensus on the population suitable for neoadjuvant therapy,but controversies remain regarding specific treatment approaches.With the continuous emergence of high-quality clinical trial results and the development of new technologies,it will be possible to establish larger-scale,geographically broader basic and clinical research initiatives,promoting advancements in personalized treatment strategies and ultimately benefiting patients.
Keywords：lung cancerneoadjuvant therapytargeted therapyimmunotherapy
Publication Date：2025-06-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：9( 454-462 )